Hofseth Biocare ASA ( (HOFBF) ) has released its Q2 earnings. Here is a breakdown of the information Hofseth Biocare ASA presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hofseth BioCare ASA is a biotechnology company specializing in the development and commercialization of high-value nutritional products and bioactive ingredients derived from sustainable marine resources, primarily focusing on human and pet health sectors.
In the second quarter of 2025, Hofseth BioCare ASA reported a mixed financial performance with a notable improvement in gross margins, despite a decline in overall revenue compared to the previous year. The company emphasized its strategic shift towards high-value human and pet health products, which contributed to a significant increase in gross margins from 34% to 46%.
Key financial highlights include total operating revenues of NOK 68.4 million for Q2 2025, down from NOK 80.4 million in the same period last year. However, the company’s operational EBITDA turned positive at NOK 1.3 million, reflecting resilient underlying operations despite non-recurring costs. The B2B human nutrition segment experienced substantial growth, with sales increasing by 180% year-over-year, driven by strong demand in Europe, China, and Southeast Asia.
The company’s R&D pipeline remains robust, with significant progress in studies related to bone health, cognitive health, and joint health. Hofseth BioCare also reported advancements in its ESG initiatives, including an improved EcoVadis Bronze rating and positive employee health metrics.
Looking ahead, Hofseth BioCare is optimistic about its growth prospects, with expectations of over 20% growth in the second half of the year, supported by improved supply conditions and the expansion of its Brilliant™ brand. The company remains focused on delivering profitable growth and long-term value creation through its strategic initiatives and innovation-driven approach.